Atombeam Appoints Cody Martinson President of Neurpac Division

Martinson Will Lead Atombeam’s Aggressive Growth Plans for Neurpac, its AI-powered Software Solution Designed to Address the Infrastructure Challenges of the AI Era

MORAGA, Calif., July 14, 2026 — Atombeam, an AI technology company that enables organizations to exponentially increase the available bandwidth of their existing infrastructure with software alone, today announced the appointment of veteran executive leader Cody Martinson as president of the company’s growing Neurpac division. Martinson will oversee all operations of the division, which includes engineering, product marketing and sales.

“Cody has a proven track record of bringing true innovation to emerging technology markets,” said Charles Yeomans, founder and CEO of Atombeam. “The demand for real-time data transmission across constrained networks — among them satellite links, cellular connections, and legacy industrial infrastructure — is accelerating faster than traditional solutions can keep up. Cody understands this problem deeply, and he understands why Neurpac is uniquely positioned to solve it.”

Powered by AI that encodes and decodes patterns within data in milliseconds, Neurpac enables compaction that makes all data far smaller, searchable, inherently secure, always accessible and lightweight for real-time exchanges. Neurpac decreases the size of data by 75% and enables any connection to process exponentially more of it, with available bandwidth on any wired or wireless network – including cellular and satellite –  increasing by a factor of 4x or more.

Neurpac can be deployed in any environment or existing stack with no new hardware in mere minutes, and works with any kind of data, including block, file, video, and SCADA. Neurpac is proven in use with financial services companies, the U.S. military and in other high-demand environments where enterprises require mission-critical data to move unimpeded in any direction even on bandwidth-constrained environments. Neurpac also enables data centers to achieve exceptional efficiency gains and is ideally suited for large-scale database transfers.

“Neurpac reflects the innovation of people like James Luciani, senior vice president of engineering at Atombeam. Previously, Jim helped found and led engineering for Akamai’s Emerging Mobile Business Unit, where he architected products that dramatically improved Quality of Experience (QoE) for mobile customers and powered in-vehicle content delivery, from firmware updates to entertainment systems. Before that, he led next-generation switching and routing product development at Ericsson, taking their internally developed family of routing products from concept through deployment,” said Martinson. “Technological milestones often require a corresponding infrastructure transformation, but what we are seeing today is unprecedented because of the sheer computing power AI requires, and its impact on existing networks, systems, and data centers. With Neurpac, businesses have an alternative to the monumental capital expenditures required to build out their infrastructure for AI and other burgeoning data and bandwidth-heavy workloads.”

Martinson brings nearly two decades of senior leadership experience to Atombeam’s Neurpac division. Before joining Atombeam he was the president, director at Telleqt, a global AI software company that specializes in enabling businesses to use predictive models to derive more value from their data. Prior to that, Martinson served as president of Artacle after serving as the CEO of DANATEQ, the provider of a self-learning cognitive analytics platform. He received his bachelor’s from Northwood University.

About Atombeam

Atombeam is an AI technology company that uses AI to overcome the infrastructure challenges exacerbated by the stateless nature of Large Language Models (LLMs) and the dramatic growth of connected machines. The company’s Neurpac solution enables organizations to shrink the size of all data, including file, block, SCADA and video by 75%. Neurpac also increases available bandwidth by up to 9x, strengthens security, and radically decreases latency with a software-only solution that can be deployed in existing stacks in just minutes. Enterprises gain the ability to do more with, and extend the life of, legacy infrastructure while simultaneously improving the performance of state-of-the-art wired, cellular and satellite networks. Atombeam is also developing the Persistent Cognitive Machine (PCM), a new AI architecture that supports continuous learning with real memory, delivering the understanding required for in-the-moment decision making in a solution light enough for chips and devices. For more information, visit www.atombeamtech.com or follow us on LinkedIn, Facebook or YouTube.

Media Contact:
Ken Phillips
Guyer Group for Atombeam
P: 781-996-1866
E: [email protected]

SOURCE Atombeam

AmeriWater Expands Clinical Water Purification Leadership Via Acquisition of Med Water Systems

DAYTON, Ohio, July 14, 2026 — AmeriWater, a leading provider of water purification solutions for critical healthcare applications, has completed the acquisition of Med Water Systems (“Med Water” or the “Company”). The addition of Med Water will significantly expand AmeriWater’s presence in the clinical laboratory and sterile processing markets, deepening its ability to serve hospitals, healthcare systems, and diagnostics facilities across the United States.

Med Water Systems is a provider of high-purity water systems for clinical analyzers and sterile processing applications, serving customers across the U.S. Founded in 2014 and headquartered in Woods Cross, Utah, Med Water has established itself as a valuable partner to major health systems by providing highly reliable water systems combined with an industry-leading national service model.

“We are excited to welcome Med Water to AmeriWater. Together, we are creating a leading clinical water platform with expanded technical expertise, service capabilities, and resources to support customers who depend on reliable, high-quality water systems every day,” said Doug Lohse, CEO of AmeriWater. “Med Water has earned a strong reputation for customer focus and technical excellence, and we look forward to building on that foundation as we continue to serve the critical needs of our customers.”

“We are excited to join AmeriWater and believe this partnership represents an important next step for Med Water Systems, our employees, and our customers,” said Richard Day, CEO at Med Water. “Together, we will have the scale, capabilities, and resources to pursue new growth opportunities while continuing to deliver the responsiveness and expertise that our customers have come to expect.”

BofA Securities acted as the exclusive financial advisor to Med Water.

About AmeriWater
AmeriWater is an industry leader in the design, manufacture, installation, and supply of water purification systems and services for the healthcare sector, including dialysis and sterile processing, as well as industrial and other applications. AmeriWater offers a broad portfolio of configurable products and components that meet stringent regulatory and customer standards. AmeriWater is headquartered in Dayton, Ohio. For more information, visit www.ameriwater.com.

About Med Water Systems
Med Water Systems is a manufacturer of laboratory water purification systems for clinical analyzers, offering the highest-purity water in high volumes for research labs, healthcare facilities, and hospitals. The Company’s product portfolio includes laboratory systems, sterile processing devices, and a recurring consumables and service offering. Med Water Systems is headquartered in Woods Cross, Utah. For more information, visit www.medwatersystems.com.

About Edgewater Capital Partners
Headquartered in Cleveland, Ohio, Edgewater Capital Partners is a sector-focused private equity firm investing in middle-market performance materials and services businesses. The firm has extensive experience investing in people, technology, and infrastructure to accelerate the growth trajectory of specialty industrials, advanced materials, specialty chemicals, and life sciences businesses. Over twenty-five years of industry-specific investing has allowed the firm to develop a deep understanding of the complexities and nuances common to these businesses. For more information, please visit www.edgewatercapital.com.

SOURCE AmeriWater

Paxos Labs Unveils Amplify Transit, Live First on Robinhood Chain With Nearly $30 Million Moved in Two Weeks

Transit brings predictable locked rate stablecoin conversion to platforms managing stablecoin balances
across major stablecoins, including USDC, USDG, and PYUSD

NEW YORK, July 14, 2026 — Paxos Labs, the enterprise-grade stablecoin infrastructure provider, today announced the launch of Amplify Transit (“Transit”), stablecoin conversion technology that enables platforms, protocols, and treasuries to move between major stablecoins across chains at predictable fees and locked rates. By providing the infrastructure for stablecoin conversion and movement, Transit allows platforms to maintain control over their customer relationships, interfaces, and margins. Already live and operating at scale, Transit has moved almost $30 million (as of July 13) on Robinhood Chain since going live on July 1, 2026.

Through a single API integration, Transit enables platforms to convert between USDC, USDG, and PYUSD with guaranteed output amounts and around-the-clock availability. Transit is chain-agnostic by design and initially supports movement across Ethereum and Robinhood Chain. Additionally, Amplify Transit has been selected as the integration of choice for Morpho, Jumper, Across, and Arcus as they build on Robinhood Chain.

Stablecoin adoption has reached a point where issuance is only the beginning,” said Bhau Kotecha, Co-Founder at Paxos Labs. “As platforms manage more stablecoins across more chains, they need infrastructure that allows them to move those assets predictably and efficiently. We built Transit to give platforms predictable economics at any scale while allowing them to maintain control over the experience and value they provide to their customers.”

As platforms begin supporting multiple stablecoins and operating across multiple chains, moving between those assets becomes increasingly complex and fragmented. A payments company may settle in PYUSD, a trading desk may hold USDC, and an exchange may operate on USDG, yet all of these assets must be converted, moved and unified before platforms can effectively put them to use.

Transit gives platforms a predictable way to manage this movement at scale. Exchanges, wallets, treasuries, fintechs, and protocols managing stablecoin balances receive a fixed fee per route, regardless of the size of the transaction, while rates are locked at the time of submission to guarantee the output amount before settlement. Conversions are available around the clock, including nights, weekends, and holidays, matching the always-on nature of the markets it serves.

“Robinhood Chain shows that stablecoins are becoming central to new financial ecosystems, and the volume Transit has already powered demonstrates the need for infrastructure that can move assets predictably from day one. Transit gives platforms the flexibility to support that growth while maintaining control over their economics and customer experience,” added Kotecha.

Transit adds to Paxos Labs’ product suite, acting as the movement layer of Amplify, the company’s infrastructure stack for platforms that want to mint, move and monetize digital assets. Amplify platforms can launch branded stablecoins, move between stablecoins and chains through Transit, and put stablecoin balances to work through Amplify Earn, all through a single integration.

ABOUT PAXOS LABS
Paxos Labs is the enterprise-grade stablecoin monetization infrastructure provider that gives platforms the tools to mint, move, and monetize digital assets, making them productive for their users. Its flagship product, the Amplify Suite, is a single integration to mint branded stablecoins, orchestrate stablecoin movement across chains, and embed yield. Incubated within Paxos and built on its $180B+ track record in tokenization and more than a decade of regulatory expertise, Paxos Labs brings institutional trust and rigor to the integration layer that makes stablecoins composable and accessible for the platforms building on them.

For more information visit paxoslabs.com

Media Contact
[email protected]

SOURCE Paxos Labs

Job Research Foundation Announces 9th Round of Funding for Researchers Investigating Causes/Treatments of Rare Multisystem Immunodeficiency Disorder

NEW YORK, July 14, 2026Job Research Foundation, which seeks to help find a cure and treatments for Job Syndrome, has announced the ninth round of grant funding. The Foundation will award up to two grants in the amount of $200,000 each over a two-year period for scientific research into the causes of, and treatments for, Job Syndrome. To date, the organization has funded a total of seventeen research projects across the world.

Grant applications can be found online at https://www.jobresearchfoundation.org/grant-proposal-application. The deadline to apply is October 16, 2026.

The long-term goal of the Foundation is to help advance research to find a cure for Job Syndrome, a rare multisystem immunodeficiency disorder. In the short term, the Foundation hopes the research will improve the treatments for current patients. Previous applicants are encouraged to re-apply as well as collaborate with other institutions to expand their research. The application process is open to researchers worldwide and awardees will be announced in January 2027.

Also known as Autosomal Dominant Hyperimmunoglobulin E Syndrome (AD-HIES), Job Syndrome was discovered in 1966 and is a rare multisystem immunodeficiency disorder found in males and females worldwide. Visit https://www.jobresearchfoundation.org/ for additional details.

MEDIA CONTACT: Risa B. Hoag, GMGPR, 845-627-3000, [email protected]

SOURCE Job Research Foundation

TiaLinx Appoints Retired Space Force Architect Maj. Gen. Clinton E. Crosier to Advisory Board

IRVINE, Calif., July 14, 2026 — TiaLinx, Inc., a leader in advanced sensing, autonomous surveillance, and space‑domain intelligence technologies, today announced that Maj. Gen. Clinton E. Crosier, USAF/USSF (Ret.), has joined the company’s Advisory Board. Maj. Gen. Crosier brings more than three decades of senior leadership experience across national security space operations, Space Domain Awareness (SDA), strategic force development, and advanced cloud technology applications.  

Maj. Gen. Crosier’s distinguished career includes serving as the Director of Space Force Planning and the principal architect of the creation of the United States Space Force. He previously served as Deputy Director of Operations at U.S. Strategic Command, where he oversaw the operational acceptance and early employment of the Geosynchronous Space Situational Awareness Program (GSSAP). As Director of Requirements for the U.S. Air Force (HAF/A5R), he led the development and approval of the original requirements for the SILENT BARKER program—two of the most consequential SDA capabilities fielded in the last decade.

 “We are honored to welcome Maj. Gen. Crosier to the TiaLinx Advisory Board,” said Dr. Fred Mohamadi, Founder and CEO of TiaLinx. “His operational insight, strategic vision, and deep understanding of SDA architectures will be invaluable as we advance our next‑generation sensing and autonomous intelligence platforms. His experience transitioning space‑based surveillance systems from concept to operational reality aligns directly with TiaLinx’s mission.”

Maj. Gen. Crosier is also the Founder and CEO of DeltaV Strategies and was the inaugural leader of the $1B Aerospace & Satellite business at Amazon Web Services, where he helped accelerate cloud adoption across the global space and geospatial industries for thousands of customers on six Continents.   

“I am excited to join TiaLinx at this pivotal moment,” said Maj. Gen. Crosier. “The company’s innovative approach to wide‑field sensing, autonomous processing, and scalable space‑domain intelligence has the potential to meaningfully enhance national security space operations. I look forward to supporting the team as they continue to push the boundaries of what is possible.”

Maj. Gen. Crosier’s appointment strengthens TiaLinx’s strategic advisory capabilities as the company expands its portfolio of advanced radar, electro‑optical, and AI‑driven surveillance technologies for government and commercial customers.

 TiaLinx develops advanced AI-assisted sensing, autonomous surveillance, and space‑domain intelligence systems that enable persistent awareness across air, ground, and orbital environments. With a strong intellectual‑property foundation and a history of innovation, TiaLinx delivers mission‑critical technologies for national security and commercial applications.

Media Contact:
Fred Mohamadi
949-285-6255
[email protected]

SOURCE TiaLinx, Inc.

Hillwood Invests in Dallas-Based Hexivon to Destroy “Forever Chemicals” in Water

Strategic investment will speed the rollout of Hexivon’s technology designed to eliminate PFAS in water for good

DALLAS, July 14, 2026Strategic investment will speed the rollout of Hexivon’s technology designed to eliminate PFAS in water for good

Hexivon, a Dallas-based water technology company, today announced a new investment from Hillwood, a Perot company. Hexivon eliminates polyfluoroalkyl substances (PFAS), also known as “forever chemicals,” from water rather than just filtering them out. The investment expands Hillwood’s infrastructure portfolio into advanced water technologies as utilities, industry and government agencies seek long-term solutions to the PFAS problem.

“We invested in Hexivon because we believe the company has developed a disruptive approach to addressing one of the most pressing environmental challenges facing communities today. We believe this collaboration can help accelerate adoption of meaningful PFAS treatment solutions across the country.”

— Ross Perot, Jr., Chairman of Hillwood

The only proven system that pulls PFAS from flowing water and destroys it for good

Most methods move PFAS around. Carbon filters, ion exchange, and reverse osmosis pull PFAS out of water, but leave waste that must be hauled off and stored. Hexivon works differently. It works at any ambient temperature and destroys PFAS at the molecular level on site. It breaks the chemicals apart and leaves nothing harmful behind.

In a 2025 pilot in Cary, North Carolina, drinking water tested at 40 parts per trillion of PFAS. After Hexivon treatment, the level was non-detectable. The system cleaned 150,000 gallons per day and made zero waste. Independent, EPA-certified labs checked the results.

Collaboration built to bring the technology to market and meet growing demand

“Hillwood brings far more than capital to this relationship. Their experience developing complex infrastructure projects, working with public-sector stakeholders and deploying long-term investment capital makes them an ideal strategic partner as we accelerate commercialisation of our PFAS destruction technology.”

— Kevin Boscamp, Chairman of Hexivon

Demand for PFAS treatment is growing fast. It is driven by new federal regulations and increased investment in water projects. In Texas, House Bill 500 (HB500) sent more than $1 billion to the Texas Water Development Board for water projects, including PFAS cleanup. Across Dallas-Fort Worth, 29 public water systems have exceeded EPA standards for PFAS, underscoring the need for treatment solutions and funding.

Together, Hillwood and Hexivon plan to accelerate deployment of PFAS destruction systems. The goal is simple: cleaner water for municipal, industrial and government customers across the United States.

Funding is available for Dallas-Fort Worth Water Systems

Texas HB500 funding can help pay for PFAS treatment in your community, and Hexivon is ready to help your system apply. The deadline is July 30, so time is short. Hexivon connects qualifying DFW water systems with engineering partners to guide the HB500 application, at no charge.

Contact Hexivon to connect with an engineering partner:
[email protected]
949-503-9341

About Hexivon
Hexivon is a Dallas-based water technology company focused on the treatment and destruction of PFAS and other emerging contaminants. Through its proprietary treatment platform, the company serves municipal utilities, industrial facilities, government agencies and environmental remediation projects across the United States. Learn more at hexivon.com.

About Hillwood
Hillwood, a Perot company, is one of the nation’s leading real estate development and investment firms with expertise spanning industrial, commercial, residential and public-sector infrastructure projects. Since 1988, Hillwood has developed and invested in transformative projects throughout North America, creating long-term value through strategic development, infrastructure investment and capital deployment.

Media Contact:
Braden Reddall
510-604-7535

SOURCE Hexivon

410 Medical Secures $12 Million in Growth Financing to Accelerate Commercial Expansion

Hospital investors lead oversubscribed financing

DURHAM, N.C., July 14, 2026 — 410 Medical, Inc., a medical device company focused on innovative technologies for emergency and critical care, today announced the completion of a $12 million financing round. Orlando Health Ventures led the round, with participation from Hatteras Venture Partners, Ballad Health, OSF Healthcare, Rex Health Ventures, CU Healthcare Innovations Fund, Sarnova, Catalyst by Wellstar, Tampa General, and a new undisclosed strategic investor.

The new funding will be used to scale 410 Medical’s commercial operations and support the launch of LifeFlow’s next-generation infuser.

“The heightened interest in this round reflects the confidence investors and customers have in 410 Medical’s mission and products,” said Kyle Chenet, Chief Executive Officer at 410 Medical. “With this funding, we’re able to expand our commercial reach, bringing LifeFlow to more clinicians and investing in the next generation of our technology. We’re grateful to Orlando Health Ventures for leading this round and excited to welcome Tampa General and an additional strategic partner to our syndicate.”

Backing Continued Commercial Growth

410 Medical’s LifeFlow products are used by more than 500 hospitals and EMS agencies across the country to help clinicians deliver fluid and blood quickly and effectively for patients experiencing sepsis, hemorrhagic shock, and other life-threatening conditions. Nearly 80,000 patients have been treated using LifeFlow. This financing enables the company to accelerate LifeFlow adoption and reach into new hospital systems and EMS agencies nationwide.

“Orlando Health Ventures is proud to lead this round and deepen our partnership with 410 Medical,” said Bobby Helmedag, Managing Director of Orlando Health Ventures. “LifeFlow addresses a critical gap in resuscitative care, and we’ve seen firsthand the impact it can have for clinicians and patients. We’re excited to support the team as they scale commercial operations and advance the next generation of the LifeFlow infuser.”

Investing in the Next Generation of LifeFlow

Alongside its commercial expansion, 410 Medical is investing in the future expansion of LifeFlow technologies. The next-generation device, planned for launch in 2027, builds on feedback from nearly ten years of experience partnering with front-line medical providers working tirelessly to provide effective resuscitation for critically ill patients. Speed, portability and ease of use are essential in these moments. The new LifeFlow technology will address these and other unmet needs. 

About 410 Medical, Inc.

Founded in 2013, 410 Medical is a North Carolina-based medical device company focused on advanced resuscitation technologies to improve the care of critically ill patients. Our lead product LifeFlow® received FDA clearance in 2016 and is used to enhance the administration of fluid and blood products for patients with sepsis, hemorrhagic shock, and other life-threatening conditions. 410 Medical is committed to providing innovative technologies, education, and support for emergency and critical care providers to deliver effective resuscitation when minutes matter.

For more information visit www.410medical.com

Media Contact:
Carla Hoffman
[email protected]

SOURCE 410 Medical, Inc.

Corgi SK Hynix 2x Daily ETF (SK) Is Now Trading: The Lowest-Cost 2x Long SK Hynix ETF at a 0.50% Expense Ratio

The Corgi SK Hynix 2x Daily ETF (Cboe BZX: SK) has the lowest expense ratio of any 2x long SK Hynix ETF, at 0.50%, compared with 0.75% to 1.50% for other 2x long SK Hynix ETFs now trading.*

NEW YORK, July 14, 2026 — Corgi, an AI fintech startup, announced that the Corgi SK Hynix 2x Daily ETF (Cboe BZX: SK) is now trading on Cboe BZX Exchange. The Fund seeks daily investment results, before fees and expenses, corresponding to 2x the daily performance of the American Depositary Receipt (ADR) of SK hynix Inc. (Nasdaq: SKHY).

At a 0.50% net expense ratio, the Corgi SK Hynix 2x Daily ETF is the lowest-cost of the U.S.-listed 2x long ETFs on the ADR of SK hynix Inc. now trading.*

The Lowest-Cost Way to Trade 2x SK Hynix

For investors searching for the lowest-cost 2x SK Hynix ETF, the Corgi SK Hynix 2x Daily ETF (SK) offers the lowest expense ratio in the category at 0.50%.* Competing 2x long SK Hynix ETFs carry net expense ratios of 0.75% (Leverage Shares SKHX), 0.95% (ProShares SKHU), 1.25% (T-REX HYNX), and 1.50% (GraniteShares SKUU), as of July 14, 2026 and subject to change.* In daily leveraged products, where positions are actively rebalanced and trading costs can affect fund expenses over time, the expense ratio is an important consideration for investors.

Why SK Hynix

SK hynix Inc. is currently one of the world’s largest memory semiconductor suppliers and a leading producer of the high-bandwidth memory (HBM) that AI accelerators depend on. The Corgi SK Hynix 2x Daily ETF seeks to give investors 2x daily exposure to this single name in a listed, transparent, exchange-traded structure, and is intended for sophisticated investors who monitor their positions daily.

“Costs are an important consideration for investors using daily leveraged ETFs, and our goal is to give investors access to leverage at a competitive cost,” said Anthony Crinieri, Portfolio Manager at Corgi Funds. “SK joins a broad lineup of more than 175 leveraged ETFs, as of July 14, 2026, designed to give investors access to leveraged investment strategies at competitive expense ratios.”

The Fund is listed on Cboe BZX Exchange and can be bought and sold throughout the trading day through broker-dealers and other financial intermediaries. Investors may pay brokerage commissions and may also incur platform, custodial, advisory, and other fees or expenses charged by their financial intermediary. Leveraged ETFs involve significant risk and are designed primarily for sophisticated investors managing positions daily. Expense ratios are only one factor to consider when evaluating an investment.

About Corgi

Founded in 2025, Corgi is an AI Financial Infrastructure Company seeking to create innovative products in insurance and finance. We are seeking to build the foundation for a new generation of financial services, with AI and technology at the core from day one. To learn more about Corgi, follow us on LinkedIn, on X, or at www.corgifunds.com.

Important Information

Investors should consider the investment objectives, risks, charges and expenses carefully before investing. The prospectus contains this and other information about the Fund and should be read carefully before investing. A copy of the prospectus is available at www.corgifunds.com.

Investing involves risk, including possible loss of principal. There is no guarantee that the Fund will achieve its investment objective. The Fund does not invest directly in the securities of SK hynix Inc.

Leveraged ETFs seek to provide a multiple of the daily performance of an underlying security or index, before fees and expenses. Due to daily compounding, returns over periods longer than one day may differ significantly from the stated multiple.

The Fund seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of its underlying security for a single day. This is measured from one net asset value calculation to the next. The Fund does not seek to achieve its stated investment objective over periods longer than one trading day. Due to the effects of compounding, the Fund’s performance over periods longer than one day may differ significantly from two times (2x) the performance of the underlying security over the same period, particularly during periods of increased market volatility.

The use of leverage magnifies both gains and losses and may result in significant losses. A relatively small movement in the underlying security can result in a substantially larger movement in the value of the Fund’s shares. The underlying ADR may experience heightened volatility, particularly in the initial period following its U.S. listing. The Fund uses derivatives, including swap agreements, to obtain leveraged exposure, which may expose the Fund to additional risks, including counterparty risk, liquidity risk, valuation risk, and tracking error. The Fund is non-diversified and concentrates its exposure in a single issuer, so the Fund’s performance depends heavily on the performance of that one security and will be more volatile than a diversified fund. The Fund is intended for sophisticated investors who understand the risks associated with leveraged investment strategies and who intend to monitor and manage their investments actively. The Fund is not intended for buy-and-hold investors.

Depositary Receipts Risk. The Fund obtains exposure through instruments referencing sponsored depositary receipts. A depositary receipt’s market value may diverge from the underlying common stock because the two trade in different markets, hours, and currencies. Depositary receipts carry the credit, custody, and operational risk of the depositary bank, and currency fluctuations between the U.S. dollar and the South Korean won will affect their value.

SK hynix Inc. is not affiliated with Corgi Strategies, LLC, Corgi, or Paralel Distributors, LLC, and has not sponsored, endorsed, sold, or promoted the Fund and makes no representation regarding the advisability of investing in the Fund.

The Fund is newly organized and has limited or no operating history. ETF shares trade at market price (not NAV), are not individually redeemable, and may trade at a premium or discount to NAV. Brokerage commissions will reduce returns.

This release is informational only and not an offer or solicitation; offers are made only by prospectus.

*Expense ratio comparison among U.S.-listed 2x long ETFs on the ADR of SK hynix Inc., based on net expense ratios obtained from each fund’s prospectus, fact sheet, and fund page as of July 14, 2026: Corgi SK Hynix 2x Daily ETF (SK) 0.50%; Leverage Shares 2x Long SK Hynix Daily ETF (SKHX) 0.75%; ProShares Ultra SK Hynix ETF (SKHU) 0.95%; GraniteShares 2x Long SK Hynix Daily ETF (SKUU) 1.50%; T-REX 2X Long SK Hynix Daily Target ETF (HYNX) 1.25%. Expense ratios are subject to change and new funds may launch, which could affect these comparisons.

Paralel Distributors, LLC (Member FINRA/SIPC) is the distributor. Corgi Strategies, LLC is the adviser. Paralel is unaffiliated with Corgi Strategies, LLC and Corgi. Control No.: COR122

Media Contact

Erika Lee
Corgi Funds
[email protected]

Justin Graiber
Corgi Funds
[email protected]

SOURCE Corgi Funds

ZeroEyes Announces $10M Investment in AI R&D and Plans to Hire 100+ Philadelphia-Area Veterans Over Next Two Years

Investment will Fuel Expansion and Accelerate Development of the Company’s Comprehensive Security Platform

PHILADELPHIA, July 14, 2026ZeroEyes, creators of the leading multi-analytics weapons detection and threat intelligence platform, today announced a planned $10 million U.S. investment in AI/ML research and development. This includes a commitment to hiring over 100 veterans in Southeastern Pennsylvania over the next 24 months to fill the roles of Technical Program Managers (AI), MLOps Engineers, and AI Solutions Specialists. The company made the announcement at Senator Dave McCormick’s 2026 Pennsylvania Defense and Innovation Summit, being held today and tomorrow at Army War College in Carlisle, Pennsylvania.

The investment will fund additional expansion, including:

  • The company’s state-of-the-art, 3,000 sq. ft. experimental AI technology lab that gives ZeroEyes the ability to generate unparalleled data, perform live demos, and test its AI weapons detection models and hardware in any environment
  • The Conshohocken-based ZeroEyes Operations Center (ZOC), the industry’s only in-house operations hub staffed primarily by military and law enforcement veterans, including former special forces personnel
  • Small drone technology capabilities, including 3D environment mapping, threat detection (ZeroEyes Aerial Detection [ZAD] Kit), and active shooter disorientation (Drones/Robots for Active Shooter Deterrence [DRASD])

Over the past few months, ZeroEyes has expanded its platform beyond firearm detection to deliver a broader, more intelligent approach to safety. New analytics capabilities including knife detection and real-time threat geolocation, as well as additional security offerings, mark a significant step toward unifying acute threat detection with everyday safety operations. The new capabilities reflect ZeroEyes’ goal to become a single, trusted platform organizations will use to secure, detect, and respond to a wide range of critical security events. These continued investments showcase the company’s commitment to further developing a comprehensive security platform that integrates preparedness, operational awareness, and investigative insights.

“This investment marks a critical milestone in our evolution into a unified threat intelligence platform that provides organizations with a single, trusted ecosystem for threat response,” said Mike Lahiff, CEO and co-founder of ZeroEyes. “We are excited to accelerate our technology roadmap while deepening our commitment to the veteran community within our home of Southeastern Pennsylvania.”

About ZeroEyes
ZeroEyes delivers an integrated suite of analytics and security tools, including capabilities such as weapons detection, real-time threat geolocation and more, designed to enhance preparedness, accelerate threat identification, and enable effective response. It provides real-time detection and actionable information for visibly brandished weapons, such as guns and knives, and alerts local staff and law enforcement with images and precise location often in a matter of seconds from the moment a gun is detected.

Founded in 2018 by Navy SEALs and elite technologists, the company pioneered human-verified gun detection to help organizations mitigate and respond to gun-related incidents. Its patented technology has been recognized by the U.S. Department of Homeland Security (DHS) as an effective anti-terrorism solution and was the first AI-based gun detection platform to achieve full SAFETY Act Designation. Building on its proven success in firearm detection, having verified over thousands of accurate firearm detections, ZeroEyes expanded its platform to address the full spectrum of modern security challenges, from defending to detecting and responding to threats.

ZeroEyes’ platform is deployed in thousands of locations across SLED, federal and defense, and commercial enterprise customers in the US, Mexico, the Caribbean, Latin America (LATAM), and India. The company also provides security assessments, system integration support, and active shooter preparedness training. Headquartered in the Greater Philadelphia area, the company continues to advance its platform using a proprietary dataset of millions of images and videos, delivering high accuracy and reliability as security needs evolve. Learn more at ZeroEyes.com.

SOURCE ZeroEyes